Related articles

You may regularly undergo health checkups, including cancer markers and imaging scans.
Yet, it’s not uncommon to hear of individuals being diagnosed with cancer shortly after receiving “normal” test results. Why does this happen?
The truth is, traditional screenings, while essential, have their limitations.
Some risks remain hidden—undetectable by standard scans or blood markers—because they originate at a cellular or molecular level, far before tumors form.
This is where RGCC (Research Genetic Cancer Centre) testing plays a unique and valuable role.

One in three men and one in four women will be diagnosed with cancer in their lifetime. Many types of cancer can develop silently over years, and by the time symptoms appear, the disease may already be in an advanced stage. Recognizing early warning signs and seeking medical advice promptly can be life-changing.

Tumor markers are substances produced either by cancer cells or by the body in response to cancer. These can be found in blood, urine, stool, body fluids, or tissues.

For individuals who have experienced cancer, monitoring for recurrence or metastasis is a vital part of ongoing care.
While traditional imaging (like CT or MRI) can reveal tumor size and location, it often fails to detect the early biological activity of cancer cells.
This is where RGCC’s advanced circulating tumor cell (CTC) testing and genetic profiling offers a valuable advantage.

Onconomics Plus is an advanced personalized oncology assessment developed by RGCC.
In addition to testing the sensitivity of circulating tumor cells to various natural substances and pharmaceutical agents,
it also includes a range of key biomarkers closely associated with tumor behavior.
These biomarkers provide vital insights for designing personalized support strategies, risk evaluation, and ongoing monitoring.